ZA201008536B - Suppression of neuroendocrine diseases - Google Patents

Suppression of neuroendocrine diseases

Info

Publication number
ZA201008536B
ZA201008536B ZA2010/08536A ZA201008536A ZA201008536B ZA 201008536 B ZA201008536 B ZA 201008536B ZA 2010/08536 A ZA2010/08536 A ZA 2010/08536A ZA 201008536 A ZA201008536 A ZA 201008536A ZA 201008536 B ZA201008536 B ZA 201008536B
Authority
ZA
South Africa
Prior art keywords
suppression
neuroendocrine diseases
neuroendocrine
diseases
Prior art date
Application number
ZA2010/08536A
Other languages
English (en)
Inventor
Stephen Johnstone
Philip Marks
Keith Foster
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0810782.3A external-priority patent/GB0810782D0/en
Priority claimed from GB0810785A external-priority patent/GB0810785D0/en
Priority claimed from GB0820884A external-priority patent/GB0820884D0/en
Priority claimed from GB0820965A external-priority patent/GB0820965D0/en
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of ZA201008536B publication Critical patent/ZA201008536B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
ZA2010/08536A 2008-06-12 2010-11-29 Suppression of neuroendocrine diseases ZA201008536B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0810782.3A GB0810782D0 (en) 2008-06-12 2008-06-12 Suppression of cancers
GB0810785A GB0810785D0 (en) 2008-06-12 2008-06-12 Suppression of neuroendocrine diseases
GB0820884A GB0820884D0 (en) 2008-11-14 2008-11-14 Suppression of neuroendocrine diseases
GB0820965A GB0820965D0 (en) 2008-11-17 2008-11-17 Suppression of cancers
PCT/GB2009/050665 WO2009150469A2 (en) 2008-06-12 2009-06-11 Suppression of neuroendocrine diseases

Publications (1)

Publication Number Publication Date
ZA201008536B true ZA201008536B (en) 2012-05-30

Family

ID=41417177

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08536A ZA201008536B (en) 2008-06-12 2010-11-29 Suppression of neuroendocrine diseases

Country Status (12)

Country Link
US (1) US20110171191A1 (enExample)
EP (3) EP2719392B1 (enExample)
JP (2) JP5728380B2 (enExample)
KR (1) KR101642363B1 (enExample)
CN (2) CN104328100B (enExample)
AU (1) AU2009259033B2 (enExample)
BR (1) BRPI0915888E2 (enExample)
CA (1) CA2727082C (enExample)
ES (2) ES2614990T3 (enExample)
IL (1) IL209855A (enExample)
WO (1) WO2009150469A2 (enExample)
ZA (1) ZA201008536B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
GB0803068D0 (en) 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
EP3194618B1 (en) 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US20170326166A1 (en) * 2014-10-17 2017-11-16 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3375871A1 (en) * 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
BR112020006827A2 (pt) 2018-01-29 2020-10-06 Ipsen Biopharm Limited neurotoxinas botulínicas clivando snare não neuronal
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
CN110801512B (zh) * 2019-11-15 2023-07-18 中国水产科学研究院黑龙江水产研究所 一种用于促进哲罗鲑性腺成熟的多肽及其应用
CN111388651B (zh) * 2020-05-09 2022-05-03 山东大学齐鲁医院 Cst-14在制备骨质疏松症治疗药物中的应用
CN113257370B (zh) * 2021-05-12 2022-09-02 中国医学科学院北京协和医院 基于临床病理基本信息和vista检测的pnet复发风险预测模型
WO2025155896A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
DE2860734D1 (en) 1977-06-08 1981-09-03 Merck & Co Inc Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
JPS5819669B2 (ja) 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
DE3264693D1 (en) 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4632979A (en) 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4803261A (en) 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
AU632468B2 (en) 1988-02-01 1993-01-07 Upjohn Company, The Renin inhibiting peptides with polar end groups
NO893088L (no) 1988-08-18 1990-02-19 Syntex Inc Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68928667T2 (de) 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
WO1990012811A1 (en) 1989-04-26 1990-11-01 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
JP2925321B2 (ja) 1989-12-08 1999-07-28 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ６位にスレオニンを有するソマトスタチン類縁体オクタペプチド
ATE127476T1 (de) 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
EP0527914A4 (en) 1990-05-04 1993-08-11 The Administrators Of The Tulane University Educational Fund Novel synthetic grf analogs
EP0531342A1 (en) 1990-05-09 1993-03-17 The Administrators Of The Tulane Educational Fund Cyclized and linear therapeutic peptides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
US6083915A (en) 1991-05-10 2000-07-04 Biomeasure, Inc. Method for treating liver cancer
US5240561A (en) 1992-02-10 1993-08-31 Industrial Progress, Inc. Acid-to-alkaline papermaking process
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
US5656727A (en) 1992-09-15 1997-08-12 The Administrators Of The Tulane Educational Fund Antagonists of LHRH
AU5727194A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
AU5668894A (en) 1992-11-13 1994-06-08 The Administrators Of The Tulane Eductional Fund Ghrh agonists
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
WO1995004752A1 (en) 1993-08-09 1995-02-16 Biomeasure, Inc. Therapeutic peptide derivatives
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
AUPM985694A0 (en) 1994-12-02 1995-01-05 Farmer, Mostyn Golf training aid
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
DE69504634T2 (de) 1995-03-13 1999-03-25 Biomeasure, Inc., Milford, Mass. Bombesin-Analogen
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5942489A (en) 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5968903A (en) 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
AU755513B2 (en) 1998-05-13 2002-12-12 Merz Pharma Gmbh & Co. Kgaa Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
DE69934337T2 (de) 1998-07-22 2007-05-24 Osprey Pharmaceuticals Ltd., Calgary Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
JP2002521456A (ja) 1998-07-30 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン類似体の使用法
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
IL146884A0 (en) 1999-06-04 2002-08-14 Sod Conseils Rech Applic Neuromedin b and somatostatin receptor agonists
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
EP1700918B1 (en) * 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US6831059B2 (en) * 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
TW200517400A (en) * 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006026780A1 (en) * 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
AU2005311086B2 (en) * 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8052979B2 (en) * 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE602006013481D1 (de) 2005-09-19 2010-05-20 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CA2658260A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
AU2007272517B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
CN102083451A (zh) * 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
US10057187B1 (en) 2015-05-27 2018-08-21 Amazon Technologies, Inc. Dynamic resource creation to connect client resources in a distributed system

Also Published As

Publication number Publication date
CN102112145A (zh) 2011-06-29
EP2719392A1 (en) 2014-04-16
EP2310028A2 (en) 2011-04-20
AU2009259033B2 (en) 2013-11-07
EP2310028B1 (en) 2016-11-16
US20110171191A1 (en) 2011-07-14
BRPI0915888E2 (pt) 2020-09-01
EP2719392B1 (en) 2019-07-24
JP5728380B2 (ja) 2015-06-03
WO2009150469A3 (en) 2010-07-15
CN104328100A (zh) 2015-02-04
JP2014195454A (ja) 2014-10-16
ES2750651T3 (es) 2020-03-26
IL209855A (en) 2013-09-30
KR101642363B1 (ko) 2016-07-25
KR20110038017A (ko) 2011-04-13
CA2727082C (en) 2019-02-26
JP5891258B2 (ja) 2016-03-22
IL209855A0 (en) 2011-02-28
CN104328100B (zh) 2019-08-23
CA2727082A1 (en) 2009-12-17
EP3590956A1 (en) 2020-01-08
BRPI0915888A2 (pt) 2020-06-30
AU2009259033A1 (en) 2009-12-17
WO2009150469A2 (en) 2009-12-17
ES2614990T3 (es) 2017-06-02
CN102112145B (zh) 2014-07-30
JP2011522560A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
ZA201008536B (en) Suppression of neuroendocrine diseases
GB2473392B (en) Methods of diagnosis
ZA201008425B (en) Suppression of cancers
GB0820970D0 (en) Suppression of cancer
IL208354A0 (en) Methods of treatment
EP2318395A4 (en) IPA INHIBITORS
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA201004765B (en) Inhibitors of iap
ZA201200751B (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
ZA201100163B (en) Unit dosage of apadenoson
ZA201004979B (en) Extracts of sclerocarya birrea
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB0820884D0 (en) Suppression of neuroendocrine diseases
GB0810785D0 (en) Suppression of neuroendocrine diseases
PL386302A1 (pl) Nowa pochodna izotiazolopirydyny
GB0811560D0 (en) Suppression of hypertension
GB0810782D0 (en) Suppression of cancers
GB0820965D0 (en) Suppression of cancers
GB0821710D0 (en) Derivatives of dihydroindolone
AU2013257527A1 (en) Unit dosage of apadenoson
GB0910052D0 (en) Suppression of hypertension
HU0800656D0 (en) Effective use of tea-composition
ZA201104656B (en) Suppression of neuroendocrine diseases
IL207009A0 (en) Extracts of sclerocarya birrea